ArticleBMC ophthalmology2025
miR-106a-5p targets CREB1 to regulate the inflammatory response in diabetic retinopathy.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundDiabetic retinopathy (DR) is a leading cause of vision loss in diabetic patients, yet early diagnostic biomarkers and targeted therapies remain limited. While miR-106a-5p has been linked to inflammatory and metabolic regulation, its role in DR remains poorly characterized.
objectiveThis study mainly explores the diagnostic value and molecular mechanism of miR-106a-5p/CREB1 in DR.
methodsThe relative expression of miR-106a-5p in 50 patients with diabetes only (NDR) and 60 patients with DR was detected by qRT-PCR. Construct a high glucose-induced ARPE-19 cell model to evaluate changes in cell proliferation, inflammatory factors such as TNF-α, IL-6, IL-1β, and CREB1 expression after transfection with miR-106a-5p mimetics. Dual luciferase validation of miR-106a-5p/CREB1 target. Clinical correlations were analyzed by Pearson and logistic regression.
resultsmiR-106a-5p was significantly downregulated in DR compared to NDR (P < 0.0001), and the ROC curve indicated that miR-106a-5p had high accuracy in DR diagnosis (AUC = 0.85). It correlated inversely with FPG (r = − 0.77), HbA1c (r = − 0.68), and inflammatory markers (IL-6, TNF-α). Binary logic analysis identified miR-106a-5p as a risk factor for diabetic retinopathy (OR = 0.08, P < 0.001). In vitro, miR-106a-5p overexpression attenuated HG-induced inflammation by targeting CREB1 (P < 0.0001).
conclusionmiR-106a-5p is considered an innovative biomarker for the detection of DR, research is exploring the part of miR-106a-5p/CREB1 in regulating inflammation as well as affecting DR occurrence, providing new ideas for DR treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.